Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib

Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib
Galapagos NV a clinical-stage biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action, recently announced the last patient randomisation in their Phase 2 clinical trial for Crohn’s disease called FITZROY. The trial is assessing the safety and efficacy of filgotinib, a Janus kinase inhibitor with selectivity for subtype JAK1 of this

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *